close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Delve Bio, Inc.

News headline image
Earlier Use of Metagenomic (mNGS) Testing Can Reduce Number of Tests Performed and Days to Diagnosis of Meningitis/Encephalitis
From Delve Bio, Inc.
Via Business Wire
News headline image
Presentations at Association for Molecular Pathology 2025 Annual Meeting Spotlight Clinical Impact of Delve Bio’s Metagenomic Sequencing Test for Improving CNS Diagnosis
From Delve Bio, Inc.
Via Business Wire
News headline image
New Data Show Early Use of Delve Bio’s Metagenomic Testing Can Reduce Need for Conventional Tests and Overall Length of Stay for Patients with Meningitis/Encephalitis
From Delve Bio, Inc.
Via Business Wire
News headline image
New Data Show Delve Bio’s Metagenomic Testing Delivers Broader, Deeper Pathogen Identification Compared to Traditional Testing
From Delve Bio, Inc.
Via Business Wire
News headline image
New Data Show Delve Bio’s Metagenomic Platform Accurately Identifies Viruses and Their Subtypes With a Single Test
From Delve Bio, Inc.
Via Business Wire
News headline image
Delve Bio to Present on Metagenomic Next Generation Sequencing (mNGS) at the American Academy of Neurology 2025 Annual Meeting
From Delve Bio, Inc.
Via Business Wire
News headline image
Delve Bio Announces Launch of its Groundbreaking Genomic Infectious Disease Test, Delve Detect
From Delve Bio, Inc.
Via Business Wire
News headline image
Delve Bio Presents Data Showing Metagenomic Next-Generation Sequencing (mNGS) Delivers Greater Diagnostic Yield Than Conventional Methods in Central Nervous System Infections
From Delve Bio, Inc.
Via Business Wire
News headline image
Delve Bio and UCSF Publish Research Demonstrating Clinical Utility of Metagenomic Next-Generation Sequencing (mNGS) for Diagnosing Serious Neurological Infections
From Delve Bio, Inc.
Via Business Wire
News headline image
Delve Bio Announces Clinical Data on the Use of Metagenomic Next-Generation Sequencing (mNGS) to Identify Pathogens Causing Central Nervous System Infections
From Delve Bio, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today